|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0011923,
umls-concept:C0013216,
umls-concept:C0032743,
umls-concept:C0087111,
umls-concept:C0205265,
umls-concept:C0600558,
umls-concept:C0677043,
umls-concept:C0681842,
umls-concept:C0871261,
umls-concept:C1261473,
umls-concept:C1511572,
umls-concept:C1555582,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C2911692
|
|
pubmed:issue |
8
|
|
pubmed:dateCreated |
2009-4-16
|
|
pubmed:abstractText |
In patients with soft-tissue sarcoma (STS), the early assessment of treatment responses is important. Using positron emission tomography/computed tomography (PET/CT) with [(18)F]fluorodeoxyglucose (FDG), we determined whether changes in tumor FDG uptake predict histopathologic treatment responses in high-grade STS after the initial cycle of neoadjuvant chemotherapy.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
pubmed-author:Allen-AuerbachMartin SMS,
pubmed-author:BenzMatthias RMR,
pubmed-author:ChowKiraK,
pubmed-author:CzerninJohannesJ,
pubmed-author:DrySarah MSM,
pubmed-author:EckardtJeff JJJ,
pubmed-author:EilberFritz CFC,
pubmed-author:ElashoffDavidD,
pubmed-author:EvilevitchVladimirV,
pubmed-author:PhelpsMichael EME,
pubmed-author:TapWilliam DWD,
pubmed-author:WeberWolfgang AWA
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
15
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2856-63
|
|
pubmed:meshHeading |
pubmed-meshheading:19351756-Adult,
pubmed-meshheading:19351756-Aged,
pubmed-meshheading:19351756-Aged, 80 and over,
pubmed-meshheading:19351756-Deoxycytidine,
pubmed-meshheading:19351756-Doxorubicin,
pubmed-meshheading:19351756-Female,
pubmed-meshheading:19351756-Fluorodeoxyglucose F18,
pubmed-meshheading:19351756-Follow-Up Studies,
pubmed-meshheading:19351756-Humans,
pubmed-meshheading:19351756-Ifosfamide,
pubmed-meshheading:19351756-Male,
pubmed-meshheading:19351756-Middle Aged,
pubmed-meshheading:19351756-Neoadjuvant Therapy,
pubmed-meshheading:19351756-Positron-Emission Tomography,
pubmed-meshheading:19351756-Prospective Studies,
pubmed-meshheading:19351756-Sarcoma,
pubmed-meshheading:19351756-Sensitivity and Specificity,
pubmed-meshheading:19351756-Soft Tissue Neoplasms,
pubmed-meshheading:19351756-Tomography, X-Ray Computed,
pubmed-meshheading:19351756-Treatment Outcome
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
FDG-PET/CT imaging predicts histopathologic treatment responses after the initial cycle of neoadjuvant chemotherapy in high-grade soft-tissue sarcomas.
|
|
pubmed:affiliation |
Ahmanson Biological Imaging Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California 90095-1782, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, Non-P.H.S.,
Research Support, N.I.H., Extramural
|
